TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01447953

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity targeted pain rehabilitation
Description: An activity and life-role targeting rehabilitation programme (ALAR) provided by one of the care givers in the multi-professional rehabilitation teams at each of the eight participating primary health care centres, by ten weekly 1-hour treatment sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Usual treatment with type of treatment modalities, number, frequency and duration of visits according to the judgement of the muli-professional teams at each primary health care centre.
Study: NCT03960892

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Management Plus (PM+)
Description: This intervention is based on the WHO treatment guidelines for conditions related to stress (WHO, 2013). It is a 5-session intervention that is delivered by trained non-specialists, and is available in individual and group delivery formats for both children and adults. PM+ includes evidence-based techniques such as; problem solving, stress management, behavioral activation, and accessing social support. It has proved to be effective by two randomized controlled trials (RCTs) in Kenya and Pakistan (Bryant, Dawson, Schafer, Sijbrandij, \& van Ommeren, 2016; Rahman, Hamdani, Awan, Bryant, Dawson, Khan, Mukhtar-ul-Haq Azeemi, et al., 2016).
Study: NCT02076646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DTIC
Description: Dacarbazine: 1 hour intravenous infusion on day 1 of each 21-cycle at a dosage of 1000 mg/m2 (fixed dose).
Study: NCT01430559

Intervention type: DRUG
Group type: OTHER
Intervention: Meloxicam
Description: 7.5mg x2 once a day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study subjects will be randomized to two treatment groups: one with Meloxicam 7.5 mgx2 once a day and another one with placebo. The duration of the interventional treatment is 12 weeks.
Study: NCT02828982

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powered ankle prosthesis
Description: This device is a commercially available powered ankle prosthesis, (BioM, Bionx, Bedford, MA) which was given FDA device exempt status.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Dynamic Response Foot
Description: This condition is a sham condition as the participant will wear the prosthesis they were clinically prescribed and usually wear.
Study: NCT03537417

Intervention type: PROCEDURE
Intervention: for thoracoscopic ablation of cervical sympathetic chain
Description: bilateral thoracoscopic ablation of cervical sympathetic chain as a treatment for hyperhidrosis
Study: NCT04138498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmethylphenidate 5 Mg Oral Capsule, Extended Release
Description: Reference listed drug (RLD) for comparative BA evaluation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmethylphenidate 5 Mg Oral Capsule, Extended Release
Description: Reference listed drug (RLD) for comparative BA evaluation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmethylphenidate 5 Mg Oral Capsule, Extended Release
Description: Reference listed drug (RLD) for comparative BA evaluation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmethylphenidate 5 Mg Oral Capsule, Extended Release
Description: Reference listed drug (RLD) for comparative BA evaluation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmethylphenidate 6.25 mg Tablet
Description: Experimental drug for comparative BA evaluation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmethylphenidate 6.25 mg Tablet
Description: Experimental drug for comparative BA evaluation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmethylphenidate 6.25 mg Tablet
Description: Experimental drug for comparative BA evaluation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmethylphenidate 6.25 mg Tablet
Description: Experimental drug for comparative BA evaluation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmethylphenidate 40 Mg Oral Capsule, Extended Release
Description: Reference listed drug (RLD) for comparative BA evaluation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmethylphenidate 40 Mg Oral Capsule, Extended Release
Description: Reference listed drug (RLD) for comparative BA evaluation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmethylphenidate 40 Mg Oral Capsule, Extended Release
Description: Reference listed drug (RLD) for comparative BA evaluation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmethylphenidate 40 Mg Oral Capsule, Extended Release
Description: Reference listed drug (RLD) for comparative BA evaluation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmethylphenidate 50 mg Tablet
Description: Experimental drug for comparative BA evaluation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmethylphenidate 50 mg Tablet
Description: Experimental drug for comparative BA evaluation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmethylphenidate 50 mg Tablet
Description: Experimental drug for comparative BA evaluation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmethylphenidate 50 mg Tablet
Description: Experimental drug for comparative BA evaluation
Study: NCT01006681

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Focetria (Monovalent MF59-Adjuvanted vaccine)
Description: 7.5 mcg Hemagglutinin H1/InfluezaA/California/7/2009 ,9.75 mg squalene MF59, 1.175 mg polysort80, 1.175 mg sorbitan trioleate~Intra muscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Focetria (Monovalent MF59-Adjuvanted vaccine)
Description: 7.5 mg Hemagglutinin H1/InfluezaA/California/7/2009, 9.75 mg squalene MF59, 1.175 mg polysirate 80, 1.175 mg sorbitan trioleate~Intramuscular injection
Study: NCT00148876

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 2500 mg/m² orally day 1-14 q day 22
Study: NCT01006681

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Focetria (Monovalent MF59-Adjuvanted vaccine)
Description: Monovalent MF59-Adjuvanted vaccine
Study: NCT00148876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 2500 mg/m² orally day 1-14 q day 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 6 mg/kg body weight every 3 weeks i.v.
Study: NCT03151187

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Teaching intervention
Description: Two two hour teaching modules on the diagnosis and treatment of disruptive behaviour disorders in children and youth

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teaching intervention
Description: Two two hour teaching modules on the diagnosis and treatment of disruptive behaviour disorders in children and youth
Study: NCT02069392

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive remediation training

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive remediation training

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine polacrilex lozenge
Description: Of interest are the effects of nicotine on cognitive remediation training benefits.
Study: NCT04629690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOLAR
Description: The participants will obtain a multidisciplinary assessment regarding their medical conditions, medication review, cognitive assessment, functional assessment, gait and balance assessment by senior clinicians and a management plan will be implemented.
Study: NCT00089466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD11070
Description: AMD11070 taken daily. Dosage dependent on arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD11070
Description: AMD11070 taken daily. Dosage dependent on arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD11070
Description: AMD11070 taken daily. Dosage dependent on arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD11070
Description: AMD11070 taken daily. Dosage dependent on arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD11070
Description: AMD11070 taken daily. Dosage dependent on arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD11070
Description: AMD11070 taken daily. Dosage dependent on arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD11070
Description: AMD11070 taken daily. Dosage dependent on arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD11070
Description: AMD11070 taken daily. Dosage dependent on arm.
Study: NCT01398748

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal glutathione - (in)GSH
Description: Intranasal glutathione-Tripeptide glutathione 100 mg/ml. 1 ml 3x per day TID X 12 weeks at 2100mg in 15 participants

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal glutathione - (in)GSH
Description: Intranasal Glutathione-Tripeptide glutathione - 200mg/ml. 1 ml 3x per day TID X 12 weeks at 4200mg in 15 participants

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Intranasal Delivery
Description: Saline administration 1ml 3x/day 12 weeks in 15 participants
Study: NCT04329312

Intervention type: RADIATION
Intervention: Thoracic computed tomography
Description: Patients undergo contrast-enhanced thoracic computed tomography as part of their routine clinical work up.
Study: NCT00586885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-alanine
Description: 6g of L-alanine (powder)once per day for the first month, twice per day for the second month, then three times per day from the third month for 10 months.
Study: NCT00979771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK706769
Description: 100 mg GSK706769 twice daily orally (BID) for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: GSK706769 matched-placebo twice daily orally (BID) for 28 days
Study: NCT03536507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACETAZOLAMIDE oral capsule
Description: Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
Study: NCT00648557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine Sodium Tablets 200 mg
Description: 3x200mcg, single dose fasting
Study: NCT02694146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: Platelet rich plasma (PRP) is a platelet concentrated obtained from autologous blood centrifugation. This concentration technique provides larger amounts of biologically active molecules, mainly growth factors that are responsible for tissue repair. PRP (platelet rich plasma) contains a higher concentration of platelets from baseline (150,000-350,000 / ul).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hylan G-F 20
Description: Hylan G-F 20 is a viscous, sterile and non-pyrogenic elasto fluid containing hylan. Hylans are byproducts from hyaluronate (hyaluronic acid sodium salt), consisting of repeating disaccharides of N-acetylglucosamine and sodium glucuronate. Hylan G-F 20 replaces and supplements the synovial fluid. It is effective at any stage of the joint pathology.
Study: NCT01781442

Intervention type: DRUG
Intervention: Temsirolimus
Description: The recommended dose of Torisel is 25 mg infused over a 30-60 minute period once a week.~Treatment will continue until disease progression or unacceptable toxicity.~The use and dosage recommendations for Torisel will take place on the basis of the approved local product document and will be adjusted solely according to medical and therapeutic necessity.
Study: NCT01718756

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group received 12 hourly 20-mL i.v. boluses of 0.9% saline starting 20 min before induction of anaesthesia, followed by a constant infusion at 10 mL/h, for 48 hrs after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous infusion
Description: The continuous infusion group received 20-mL i.v. boluses of lornoxicam 0.8 mg/mL starting 20 min before induction of anaesthesia followed by a 12 hourly 20-mL i.v. boluses of 0.9% saline and a constant infusion at 10 mL/h of lornoxicam 0.13 mg/mL, for 48 hrs. after surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scheduled
Description: The scheduled group received an 12 hourly 20-mL i.v. boluses of lornoxicam 0.8 mg/mL starting 20 min before induction of anaesthesia followed by a constant infusion at 10 mL/h of 0.9% saline, for 48 hrs after surgery (supplied by Xefo, JPI, Saudi Arabia), starting 20 min before induction of anaesthesia.
Study: NCT01928862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prepopik® ½ Sachet x 2 (9-12 years)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prepopik® 1 Sachet x 2 (9-12 years)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral polyethylene glycol (PEG) based preparation (9-12 years)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prepopik® 1 Sachet x 2 (13-16 years)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral polyethylene glycol (PEG) based preparation (13-16 years)
Study: NCT01752855

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: New formulation adalimumab
Description: New formulation adalimumab 40 mg every other week
Study: NCT01115595

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: Dermatophagoides pteronyssinus from ALK company

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Injection by buffer solution WITH standard allergic medication (oral antihistamine and/or topical nasal steroid)
Study: NCT01100242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade and Sorafenib
Description: Velcade will be administered intravenously; sorafenib will be self-administered on an outpatient basis. At least 2 courses will be administered to each patient unless there is early progression of disease or unacceptable toxicity. Repeated courses may be given to patients who benefit from the treatment (complete or partial remission or stabilization of disease)
Study: NCT00314574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab (Xolair)
Description: Omalizumab (Xolair) was administered by subcutaneous (SC) injection every 2 or 4 weeks. Xolair was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that were reconstituted with Sterile Water for Injection (SWFI), USP.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo was administered by subcutaneous (SC) injection every 2 or 4 weeks. Placebo contained the same ingredients as the lyophilized formulation of Xolair,excluding omalizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: Minimum dose of 500 µg of fluticasone dry-powder inhaler or its equivalent ex-valve dose twice a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: corticosteroids
Description: Minimum dose of 500 µg of fluticasone dry-powder inhaler or its equivalent ex-valve dose twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: long-acting beta-agonists
Description: 50 µg salmeterol twice daily or 12 µg formoterol twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: long-acting beta-agonists
Description: 50 µg salmeterol twice daily or 12 µg formoterol twice daily.
Study: NCT03198377

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS: Randomized frequency modulation
Description: Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are:~Frequency modulation: randomized pattern (from 80 to 120 Hz) Pulse width 200 microseconds

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS: Scan 6/6 of frequency modulation
Description: Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are:~Frequency modulation: Scan of frequency from 80 to 120 Hz in 6/6 mode (frequency sweep from 80 Hz to 120 Hz in 6 seconds and from 120 to 80 Hz in 6 secons) Pulse width 200 microseconds

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS: Fixed frequency
Description: Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are:~Fixed frequency at 100 Hz Pulse width 200 microseconds

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Electrodes are placed over the course of the superficial radial nerve in the right forearm for a 20 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel.
Study: NCT04649164

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer mentor support and caregiver intervention
Description: Sixteen-week modular curriculum with printed/online workbook, additional resources, and weekly phone discussion with Lewy Body Dementia peer mentor.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Peer mentor support and caregiver intervention
Description: Sixteen-week modular curriculum with printed/online workbook, additional resources, and weekly phone discussion with Lewy Body Dementia peer mentor.

Intervention type: OTHER
Group type: OTHER
Intervention: Focus group to provide feedback on educational materials and mentoring program
Description: Participation in a 2-3 hour focus group to review pilot and revised materials and provide feedback
Study: NCT04338438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate tablets combined with S-1 capsules
Description: Apatinib Mesylate tablets combined with S-1 capsules, p.o.
Study: NCT00521196

Intervention type: DEVICE
Group type: OTHER
Intervention: DC Stimulator (Transcranial Direct Current Stimulator)
Description: Subjects will receive a total of 10 sessions of either active tDCS or sham tDCS over a four-week period (administered every other day during weekdays over the course of one month). During each tDCS session, two electrodes are placed over selected areas of the brain. The anode is placed on the motor cortex contralateral to the side where migraines predominant; the cathode is placed near the supraorbital area, opposite the anode. A small battery powered device drives 2 mA of direct current through the two electrodes. The direct current will flow through the electrodes, penetrate the scalp, and create a flow of electrical current in the brain. The procedure will last 20 minutes. For sham tDCS, an alternate method of stimulation will be used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DC Stimulator (Transcranial Direct Current Stimulator)
Description: Subjects will receive a total of 10 sessions of either active tDCS or sham tDCS over a four-week period (administered every other day during weekdays over the course of one month). During each tDCS session, two electrodes are placed over selected areas of the brain. The anode is placed on the motor cortex contralateral to the side where migraines predominant; the cathode is placed near the supraorbital area, opposite the anode. A small battery powered device drives 2 mA of direct current through the two electrodes. The direct current will flow through the electrodes, penetrate the scalp, and create a flow of electrical current in the brain. The procedure will last 20 minutes. For sham tDCS, an alternate method of stimulation will be used.
Study: NCT00225381

Intervention type: DEVICE
Intervention: connection of measuring device to anesthesia circuit
Description: same as name

Intervention type: DEVICE
Intervention: connection of measuring device to anesthesia circuit
Description: same as name

Intervention type: DEVICE
Intervention: connection of measuring device to anesthesia circuit
Description: same as name

Intervention type: DEVICE
Intervention: connection of measuring device to anesthesia circuit
Description: same as name

Intervention type: DEVICE
Intervention: connection of measuring device to anesthesia circuit
Description: same as name

Intervention type: PROCEDURE
Intervention: drawing of blood sample through an arterial line, placed according to clinical criteria by primary anesthesia team
Description: same

Intervention type: PROCEDURE
Intervention: changing operating room bed position (head down and up position)
Description: same

Intervention type: PROCEDURE
Intervention: adding PEEP during anesthesia
Description: same

Intervention type: PROCEDURE
Intervention: placement of esophageal Doppler for cardiac output measurements
Description: same

Intervention type: DEVICE
Intervention: Humidity sensor
Description: Small conventional anesthesia T piece including tiny 2 thermometer inside

Intervention type: DEVICE
Intervention: Humidity sensor
Description: Small conventional anesthesia T piece including tiny 2 thermometer inside

Intervention type: DEVICE
Intervention: Humidity sensor
Description: Small conventional anesthesia T piece including tiny 2 thermometer inside
Study: NCT00648557

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synthroid Tablets 200 mg
Description: 3x200mcg, single dose fasting
Study: NCT02164266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo daily oral administration
Study: NCT01476982

Intervention type: DEVICE
Intervention: ClearView Scan
Description: Assessment with ClearView device
Study: NCT02164266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6799477
Description: Daily oral administration of RO6799477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6799477
Description: Daily oral administration of RO6799477